Résumé
Introducción. La prueba de provocación oral (PPO) para el diagnóstico de alergia a las proteínas de la leche de la vaca (APLV) presenta riesgos y requiere de recursos. Nuestro objetivo fue evaluar condiciones y pruebas complementarias para identificar una alta probabilidad de APLV. Población y métodos. Análisis secundario sobre estudio de pacientes atendidos en una unidad de alergia entre 2015 y 2018. Se determinaron las probabilidades prepruebas asociadas a los síntomas y sus combinaciones, y las probabilidades pospruebas luego de realizadas pruebas cutáneas y determinación de inmunoglobulina E (IgE) sérica. Resultados. Se evaluó la información de 239 pacientes. Se observaron probabilidades mayores al 95 % en pacientes con angioedema y combinación de urticaria y vómitos. Usando puntos de corte propuestos por Calvani et al., la combinación de vómitos con rinitis, sin angioedema, también superó el 95 %. Conclusión. Se ofrece una metodología para identificar pacientes en los que puede diagnosticarse APLV sin realización de PPO.
Introduction. The oral food challenge (OFC) for the diagnosis of cow's milk protein allergy (CMPA) poses risks and requires resources. Our objective was to assess conditions and complementary tests used to identify a high probability of CMPA. Population and methods. Secondary analysis of a study of patients seen at a unit of allergy between 2015 and 2018. Pre-testing probabilities associated with symptoms and their combinations and post-testing probabilities after skin prick testing and serum immunoglobulin E (IgE) levels were determined. Results. The data from 239 patients were assessed. A probability greater than 95% was observed for angioedema and a combination of urticaria and vomiting. Based on the cut-off points proposed by Calvani et al., the combination of vomiting with rhinitis, without angioedema, also exceeded 95%. Conclusion. A methodology is provided to identify patients in whom CMPA may be diagnosed without an OFC.
Sujets)
Humains , Animaux , Nourrisson , Hypersensibilité au lait/diagnostic , Hypersensibilité au lait/épidémiologie , Angioedème/complications , Vomissement , Bovins , Tests cutanés/méthodes , Protéines de lait/effets indésirablesRésumé
Abstract The authors report the case of a 71-year-old woman presented to the Emergency Department with acute ischemic stroke. She was treated with rt-PA and interventional endovascular revascularization and developed rapidly progressing angioedema that led to emergency intubation. The standard treatment was not very effective and the swelling improved after infusion of fresh frozen plasma. Angioedema after rt-PA infusion could be a life-threatening emergency that requires quick airway management by skilled professionals. As this condition is triggered by several factors, such as unregulated histamine and bradykinin production, the traditional treatment recommended by the guidelines may not be sufficient and the use of FFP can be considered as a safe and valuable aid.
Sujets)
Humains , Femelle , Adulte d'âge moyen , Sujet âgé , Accident vasculaire cérébral ischémique/complications , Angioedème/induit chimiquement , Angioedème/thérapie , Plasma sanguin , Histamine , Prise en charge des voies aériennesRésumé
Abstract Acquired angioedema with C1 inhibitor deficiency (AAE-C1INH) is a very rare condition of bradykinin-mediated angioedema. One of its major complications is potentially life-threatening, laryngeal edema. We report a 53-year-old woman with AAE-C1INH proposed for an elective broncofibroscopy. The direct stimulation caused by broncofibroscopy poses a high risk of angioedema, thus presenting an anesthetic challenge. Due to the risk of death, it is essential to adopt preventive measures. Short-term prophylaxis was performed, and the acute treatment was readily available. A well-structured multidisciplinary periprocedural plan makes it possible to safely approach the airway, in a remote area of the hospital.
Sujets)
Humains , Femelle , Jeune adulte , Angio-oedèmes héréditaires/thérapie , Anesthésiques , AngioedèmeRésumé
A urticária crônica é uma condição que afeta mais de um milhão de brasileiros, com grande impacto na qualidade de vida. Mesmo com diretrizes bem difundidas para o seu diagnóstico e tratamento, seu manejo pode ser desafiador em pacientes pediátricos, idosos e gestantes. Para auxiliar o médico especialista nestes casos, o Departamento Científico de Urticária da Associação Brasileira de Alergia e Imunologia elaborou esta revisão com as principais dúvidas e dificuldades referentes ao tema nestes grupos de pacientes.
Chronic urticaria is a condition that affects more than a million Brazilians with a significant impact on quality of life. Although there are well-established guidelines for diagnosis and treatment, the management of chronic urticaria may be challenging in pediatric, older, and pregnant patients. With the purpose of helping specialists manage these cases, the Urticaria Scientific Department of the Brazilian Association of Allergy and Immunology prepared this review with the most common doubts and difficulties about this topic in those patient groups.
Sujets)
Humains , Grossesse , Nourrisson , Enfant d'âge préscolaire , Enfant , Sujet âgé , Sujet âgé de 80 ans ou plus , Femmes enceintes , Diagnostic différentiel , Omalizumab , Urticaire chronique , Antihistaminiques des récepteurs H1 , Patients , Médecins , Qualité de vie , Sociétés médicales , Thérapeutique , Urticaire , Lactation , Diagnostic , Allergie et immunologie , AngioedèmeRésumé
A urticária aguda é uma causa frequente de consulta com alergistas, caracterizada por urticas e/ou angioedema. Embora autolimitada e benigna, pode causar desconforto significativo e raramente representar uma doença sistêmica grave ou reação alérgica com risco de vida. Nesta revisão, elaborada pelo Departamento Científico de Urticária da Associação Brasileira de Alergia e Imunologia, foram abordadas as principais questões referentes ao tema para auxiliar o médico especialista e generalista.
Acute urticaria is a frequent cause of consultations with allergists, being characterized by wheals and/or angioedema. Although self-limited and benign, it may cause significant discomfort and uncommonly represent a serious systemic disease or life-threatening allergic reaction. In this review prepared by the Urticaria Scientific Department of the Brazilian Association of Allergy and Immunology, the main questions about this topic are addressed to help specialists and general practitioners.
Sujets)
Humains , Urticaire , Épinéphrine , Hypersensibilité au lait , Hypersensibilité à l'oeuf , Hypersensibilité médicamenteuse , Hypersensibilité aux fruits de mer , Hypersensibilité aux noix et aux arachides , Antihistaminiques des récepteurs H1 , Anaphylaxie , Morsures d'araignées , Médecins , Sociétés médicales , Thérapeutique , Anti-inflammatoires non stéroïdiens , Syndrome de Sweet , Eczéma de contact allergique , Hormones corticosurrénaliennes , Syndrome hyperéosinophilique , Syndrome de Schnitzler , Mastocytose cutanée , Diagnostic , Allergie et immunologie , Érythème , Angio-oedèmes héréditaires , Hypersensibilité alimentaire , Allergologues , Hypersensibilité , AngioedèmeRésumé
Introdução: A urticária crônica é uma doença com prevalência em pelo menos 0,1% da população, definida pela presença de pápulas pruriginosas, angioedema ou ambos por período superior a seis semanas. Os pacientes com urticária crônica têm um severo prejuízo na qualidade de vida. Objetivo: Avaliar o impacto da urticária crônica na qualidade de vida dos portadores da doença dentro de um serviço especializado no estado de Sergipe. Métodos: Trata-se de um estudo descritivo observacional a partir de dados coletados de 40 pacientes atendidos, em 2021, no Serviço de Alergia e Imunologia do Ambulatório de Alergia e Imunologia do Decós Day Hospital, através de dois questionários específicos para a avaliação da qualidade de vida na urticária crônica: o Chronic Urticaria Quality of Life Questionnaire e o Urticaria Control Test. Resultados: Foi possível identificar uma correlação positiva, através do questionário Urticaria Control Test, entre a intensidade dos sintomas e a piora da qualidade de vida (r = 0,774; p < 0,001). Também foi possível identificar uma correlação positiva entre a intensidade dos sintomas e a piora da qualidade de vida, desta vez mensurada pela escala Chronic Urticaria Quality of Life Questionnaire (r = 0,768; p < 0,001). Noventa por cento dos pacientes afirmaram se sentir cansados durante o dia porque não dormiram bem, 87,5% sentem dificuldade para se concentrar, 90% sentem-se nervosos, 80% afirmaram sentirem-se para baixo, 75% disseram ter vergonha das lesões da urticária que aparecem no corpo, e 60% tem vergonha de frequentar lugares públicos. Conclusões: A urticária crônica compromete a qualidade de vida, medida pelos questionários Urticaria Control Test e Chronic Urticaria Quality of Life Questionnaire. O comprometimento da qualidade de vida dos doentes com urticária crônica ocorre principalmente nos aspectos psicológicos, nos relacionamentos sociais e na qualidade do sono.
Introduction: Chronic urticaria is a disease with a prevalence in at least 0.1% of the population, defined by the presence of pruritic papules, angioedema or both for a period longer than six weeks. Patients with chronic urticaria have a severe loss in quality of life. Objective: To assess the impact of chronic urticaria on the quality of life of patients with the disease within a specialized service in the state of Sergipe. Methods: This is a descriptive observational study based on data collected from 40 patients treated, in 2021, at the Allergy and Immunology Service of the Allergy and Immunology Outpatient Clinic of Decós Day Hospital, using two specific questionnaires for quality assessment of life in chronic urticaria: the Chronic Urticaria Quality of Life Questionnaire and the Urticaria Control Test. Results: It was possible to identify a positive correlation, through the Urticaria Control Test questionnaire, between the intensity of symptoms and the worsening of quality of life (r = 0.774, p < 0.001). It was also possible to identify a positive correlation between the intensity of symptoms and worsening quality of life, this time measured by the Chronic Urticaria Quality of Life Questionnaire scale (r = 0.768, p < 0.001). 90% said they felt tired during the day because they didnt sleep well, 87.5% found it difficult to concentrate, 90% felt nervous, 80% said they felt down, 75% said they were ashamed of the urticaria lesions that appear on the body and 60% are ashamed to go to public places. Conclusions: Chronic urticaria compromises quality of life, as measured by the Urticaria Control Test and the Chronic Urticaria Quality of Life Questionnaire. The impairment of the quality of life of patients with chronic urticaria occurs mainly in the psychological aspects, in social relationships and in the quality of sleep.
Sujets)
Humains , Qualité de vie , Urticaire chronique , Patients , Honte , Signes et symptômes , Sommeil , Études transversales , Enquêtes et questionnaires , Allergie et immunologie , Qualité du sommeil , AngioedèmeRésumé
Abstract Hereditary angioedema (HAE) is a rare disease with an autosomal dominant heredity pattern, due to mutations in the gene encoding the C1 esterase inhibitor. The onset of symptoms usually occurs during childhood. Clinically, it is characterized by repeated episodes of angioedema that may affect the skin, abdomen and larynx/pharynx. The occurrence of attacks and their severity are unpredictable and can be fatal without the appropriate treatment. We present the case of an asymptomatic 65-year-old woman, with a history of three adult children diagnosed with HAE. Despite the high probabilities of being a carrier of the mutation, she had not been previously studied. Diagnosis of HAE in a family member would require screening of all at-risk relatives. Early diagnosis is essential to establish a correct and timely therapeutic strategy in order to reduce the morbidity and mortality associated with the disease.
Resumen El angioedema hereditario (HAE) es una enfermedad rara, con un patrón de herencia autosómico dominante, debida a mutaciones en el gen que codifica el inhibidor de la C1 esterasa. El inicio de los síntomas suele ocurrir durante la infancia. Clínicamente se caracteriza por episodios recurrentes de angioedema que pueden afectar la piel, el abdomen y la laringe/faringe. La ocurrencia de los ataques y su gravedad son imprevisibles, y puede resultar fatal sin el tratamiento apropiado. Presentamos el caso de una mujer de 65 años de edad, asintomática, con antecedente de tres hijos adultos con diagnóstico de HAE, quién pese a la alta probabilidad de ser portadora de la mutación, no había sido estudiada previamente. El diagnóstico de HAE en un integrante de la familia obligaría a realizar estudios de cribado en todos los familiares en riesgo. El diagnóstico temprano resulta fundamental para establecer una estrategia terapéutica correcta y oportuna, disminuyendo así la morbimortalidad asociada a la enfermedad.
Sujets)
Humains , Femelle , Sujet âgé , Angio-oedèmes héréditaires/diagnostic , Angio-oedèmes héréditaires/génétique , Angioedème , Famille , C1 Inhibiteur , MutationRésumé
Abstract Background: There are few epidemiological studies of urticaria, published in the indexed literature (PubMed/Medline). Objective: The study aimed to evaluate the epidemiological and clinical data among patients with urticaria/angioedema attending a reference clinic in Brazil. Methods: Two hundred sixty-seven patients were evaluated retrospectively considering demographic data, time course of the disease, triggering symptoms, the presence of angioedema, complementary laboratory tests including total blood count, reactive-C protein, erythrocyte sedimentation rate, IgE serum levels, and other, as necessary. Results: The most commonly diagnosed type of urticaria was chronic spontaneous urticaria (56.93%). Angioedema was associated with chronic urticaria in 108 patients (40.08%). Study limitations: Unicentered and retrospective. Conclusion: Some relevant findings in this study are the observation of a female prevalence of cases (4-females: 1-man), a result more elevated than demonstrated in previous studies in Europe and Asia, the median age was 43-years old and the delay of time between the diagnosis of urticaria and the admission for treatment in a specialized center was approximately 2-years. Other multicenter studies can better establish these differences in Brazilian patients.
Sujets)
Humains , Femelle , Adulte , Urticaire/épidémiologie , Angioedème/diagnostic , Angioedème/épidémiologie , Brésil/épidémiologie , Maladie chronique , Études rétrospectivesRésumé
A urticária é uma lesão cutânea eritematosa, edematosa e pruriginosa, mais prevalente em mulheres entre 30 a 50 anos de idade, sendo classificada em aguda ou crônica. O quadro clínico da urticária crônica espontânea é desencadeado independentemente de estímulos exógenos, podendo ser acompanhado de angioedema em 40% dos casos. O diagnóstico é clínico e a doença pode ser monitorada com escores. O tratamento da urticária crônica espontânea é baseado em anti-histamínicos H1 de segunda geração como primeira linha. A segunda linha se baseia no aumento da dose de anti-histamínicos H1 em até quatro vezes a dose habitual, a terceira linha consiste na associação de imunobiológicos como o omalizumabe, e a quarta linha no uso de ciclosporina. Este relato de caso teve como objetivo analisar a eficácia e segurança do tratamento com dupilumabe na urticária crônica espontânea refratária ao omalizumabe, utilizando os escores de atividade da urticária e o questionário de qualidade de vida em dermatologia. A partir dos resultados obtidos, verificou-se sucesso terapêutico com dupilumabe, que se manteve mesmo após suspensão do medicamento. O uso off label do dupilumabe justificou-se pelo seu mecanismo de ação na fisiopatologia da doença. Este é o primeiro relato de caso brasileiro do uso de dupilumabe para urticária crônica espontânea refratária ao omalizumabe.
Urticaria is an erythematous, edematous, and pruritic skin lesion, most prevalent in women between 30 and 50 years of age, and classified as acute or chronic. The clinical features of spontaneous chronic urticaria are triggered regardless of exogenous stimuli and may be accompanied by angioedema in 40% of cases. The diagnosis is clinical and the disease can be monitored with scores. The first-line treatment of spontaneous chronic urticaria is based on second-generation H1 antihistamines. The second-line treatment is based on increasing the dose of H1 antihistamines by up to four times the standard dose, the third line consists of the association with biologics such as omalizumab, and the fourth line consists of the use of cyclosporine. The present case report aimed to analyze the efficacy and safety of dupilumab treatment for chronic spontaneous urticaria refractory to omalizumab, quantifying clinical improvement and quality of life using urticaria activity scores and a dermatology quality of life questionnaire, respectively. The results obtained showed therapeutic success with dupilumab, which was maintained even after drug suspension. Offlabel use of dupilumab was justified by its mechanism of action in the pathophysiology of the disease. This is the first Brazilian case report of the use of dupilumab for chronic spontaneous urticaria refractory to omalizumab.
Sujets)
Humains , Femelle , Jeune adulte , Anticorps monoclonaux humanisés , Omalizumab , Urticaire chronique , Antihistaminiques , Antihistaminiques des récepteurs H1 , Thérapeutique , Efficacité en Santé Publique , Ciclosporine , Dosage , AngioedèmeRésumé
Abstract Objectives: To describe the hereditary angioedema to improve awareness of this condition and reduce diagnostic delay. Data sources: Relevant articles in the MEDLINE database through PubMed. Data synthesis: Hereditary angioedema is rare and has an autosomal dominant pattern of inheritance. Its onset occurs mainly in childhood, but there is an important delay in the diagnosis. In the most frequent phenotype, there is a quantitative and/or functional deficiency in the C1esterase inhibitor protein, which regulates the activation of the complement, contact and fibrinolysis systems with greater formation of bradykinin, the main mediator of angioedema. There is a third type, the hereditary angioedema with a normal C1 inhibitor level, which is rare in children. Clinical manifestations are characterized by recurrent angioedema attacks, mainly in the extremities, abdomen and upper airways, which can progress to asphyxia and death. The main triggers are mechanical trauma, infections and stress. The diagnosis is attained by patient clinical picture and decreased serum levels of C4 and C1esterase inhibitor or its function. In hereditary angioedema with a normal C1 inhibitor, there is no change in these parameters, thus requiring a genetic study. Treatment is based on the use of attack medications and long and short-term prophylaxis. Conclusions: Hereditary angioedema is little known by pediatricians due to the significant delay in diagnosis of this condition, whose onset usually begins in childhood. The presence of recurrent angioedema that does not respond to treatment with antihistamines, corticosteroids and adrenaline should increase the diagnostic suspicion.
Sujets)
Humains , Enfant , Angio-oedèmes héréditaires/diagnostic , Angio-oedèmes héréditaires/génétique , Angioedème , Bradykinine , Retard de diagnostic , PédiatresRésumé
Introdução: A urticária é uma doença caracterizada pelo desenvolvimento de urticas, angioedema ou ambos. Convencionalmente a urticária pode ser dividida, quanto a sua duração, em duas formas: aguda (UA), quando os sintomas duram menos de seis semanas, e crônica (UC), com seis semanas ou mais de evolução. A COVID-19, enfermidade causada pelo coronavírus SARSCoV- 2, foi inicialmente descrita no final de 2019. A doença se apresenta por sintomas gripais, pneumonia, síndrome respiratória aguda grave e diarreia. Entretanto, o conhecimento atual sugere que a doença seja considerada sistêmica. Objetivo: Descrever as características dos pacientes que apresentaram UA ou exacerbação de UC durante infecção por COVID-19, atendidos em um Centro de Referência e Excelência em Urticária (GA2LEN UCARE). Métodos: De março a agosto de 2020 foram atendidos 12 pacientes com UA ou exacerbação da UC, diagnosticados com COVID-19. Resultados: Dentre os doze pacientes, 11 (92%) eram femininos. Quatro (33%) apresentaram UA entre o 1-6° dia da doença. Oito pacientes (67%) apresentaram exacerbação de UC, precedendo sintomas da COVID-19. Dentre estes, 5 (71%) apresentaram angioedema. Um aspecto importante foi o curso benigno destes pacientes, sem necessidade de hospitalização. Conclusão: Apesar da COVID-19 definir-se por doença respiratória, é essencial o olhar atento e criterioso para outras manifestações clínicas, como as cutâneas, que podem se apresentar como sintomas isolados ou associados. A identificação desta condição pode levar a uma melhoria no diagnóstico e terapia da COVID-19, bem como a uma aplicação mais rápida de práticas de quarentena.
Introduction: Urticaria is a disease characterized by the development of wheals, angioedema, or both. Conventionally, urticaria can be divided, on the basis of duration, into two forms: acute (AU), when symptoms last less than 6 weeks, and chronic (CU), when they last 6 weeks or more. COVID-19, a disease caused by the SARS-CoV-2 coronavirus, was first described in late 2019. The disease may manifest as flu-like symptoms, pneumonia, severe acute respiratory syndrome, and diarrhea. However, current knowledge suggests that the disease is systemic. Objective: To describe the characteristics of patients who presented with AU or exacerbation of CU during infection, treated at a Urticaria Center of Referral and Excellence (GA2LEN UCARE). Methods: From March to August 2020, 12 patients with AU or CU exacerbation who were diagnosed with COVID-19 were treated. Results: Among the 12 patients, 11 (92%) were female. Four patients (33%) had AU between days 1 and 6 of the disease. Eight patients (67%) had CU exacerbation preceding symptoms of COVID-19. Among these, 5 (71%) had angioedema. An important aspect was the benign course of these patients, with no need for hospitalization. Conclusion: Although COVID-19 is defined by respiratory disease, it is essential to look carefully for other clinical manifestations, such as cutaneous symptoms, which can be isolated or associated. The identification of this condition can lead to an improvement in the diagnosis and therapy of COVID-19, as well as a faster application of quarantine practices.
Sujets)
Humains , Urticaire , Urticaire chronique , SARS-CoV-2 , COVID-19 , Angioedème , Maladies de l'appareil respiratoire , Signes et symptômes , Coronavirus , DiagnosticRésumé
Episodic angioedema with eosinophilia (EAE) is a rare condition characterized by recurrent attacks of angioedema and urticaria accompanied by a marked elevation of peripheral eosinophil count. We report the case of a young female patient diagnosed with EAE associated with urticarial vasculitis. A 40-year-old female patient was admitted to our institution due to recurrent episodes of cheek and eyelid angioedema in the previous year. Episodes of facial angioedema lasted for two months with spontaneous remission afterwards. In addition, she presented pruritic and painful skin eruptions of erythematous circles, which persisted for longer than 24 h, that were palpable, somewhat purplish, and more pronounced on the face, arms, and trunk. Laboratory investigation showed a sustained elevation of white cell counts with marked eosinophilia. Serum IgM, IgE, and IgA were normal; IgG was slightly elevated. C1-esterase inhibitor and tryptase test were normal. Reverse transcriptase-polymerase chain reaction was performed for detection of FIP1L1-PDGFRA and BCR-ABL rearrangements. None of these alterations were found. Skin biopsies were suggestive of urticarial vasculitis. The patient was submitted to esophagogastroduodenoscopy, which showed mild chronic gastritis, with no eosinophilic infiltration. Cardiac dimensions and function were normal. Abdominal ultrasound and total body CT-scan failed to show lymphadenopathy, organomegaly, and tumors. We report the first case of association between episodic angioedema with eosinophilia and urticarial vasculitis. It is possible that both conditions share a physiopathological mechanism, suggesting that it is not just a chance association.
Sujets)
Humains , Femelle , Adulte , Urticaire/complications , Vascularite , Éosinophilie/complications , Angioedème/complications , Angioedème/diagnostic , PeauRésumé
La queilitis granulomatosa es una entidad granulomatosa no infecciosa, poco frecuente, que se presenta como un aumento de volumen persistente de la región orofacial. El estudio histológico, junto con la exclusión de otras patologías granulomatosas son necesarios para su diagnóstico, especialmente cuando no se presenta con la triada clásica del Síndrome de Merkelsson Rosenthal. Presentamos dos casos de queilitis granulomatosa y una revisión de la literatura disponible.
Granulomatous cheilitis is a rare, non-infectious, granulomatous entity that presents as a persistent swelling of the orofacial region. Histological study together with the exclusion of other granulomatous diseases are necessary for the diagnosis, especially when the presentation is not the classic triad of Merkelsson Rosenthal Syndrome. We present two cases of granulomatous cheilitis and a review of the available literature.
Sujets)
Humains , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Granulomatose orofaciale , Syndrome de Melkersson-Rosenthal/diagnostic , Diagnostic différentiel , Hypersensibilité alimentaire/étiologie , Angioedème/complications , Syndrome de Melkersson-Rosenthal/thérapieRésumé
ABSTRACT Angioedema attacks are common causes of emergency care, and due to the potential for severity, it is important that professionals who work in these services know their causes and management. The mechanisms involved in angioedema without urticaria may be histamine- or bradykinin-mediated. The most common causes of histamine-mediated angioedema are foods, medications, insect sting and idiopathic. When the mediator is bradykinin, the triggers are angiotensin-converting enzyme inhibitors and factors related to acquired angioedema with deficiency of C1-inhibitor or hereditary angioedema, which are less common, but very important because of the possibility of fatal outcome. Hereditary angioedema is a rare disease characterized by attacks of edema that affect the subcutaneous tissue and mucous membranes of various organs, manifesting mainly by angioedema and abdominal pain. This type of angioedema does not respond to the usual treatment with epinephrine, antihistamines and corticosteroids. Thus, if not identified and treated appropriately, these patients have an estimated risk of mortality from laryngeal edema of 25% to 40%. Hereditary angioedema treatment has changed dramatically in recent years with the development of new and efficient drugs for attack management: plasma-derived C1 inhibitor, recombinant human C1-inhibitor, bradykinin B2 receptor antagonist (icatibant), and the kallikrein inhibitor (ecallantide). In Brazil, plasma-derived C1 inhibitor and icatibant have already been approved for use. Proper management of these patients in the emergency department avoids unnecessary surgery and, especially, fatal outcomes.
RESUMO As crises de angioedema são causas comuns de atendimentos nas emergências, e devido ao potencial de gravidade, é importante que os profissionais que atuam nesses serviços conheçam suas causas e abordagem. Os mecanismos envolvidos no angioedema sem urticas podem ser histaminérgicos ou mediados por bradicinina. As causas mais comuns de angioedema mediado por histamina são alimentos, medicamentos, ferroada de insetos e idiopática. Quando o mediador é a bradicinina, os desencadeantes são os inibidores da enzima conversora de angiotensina e fatores relacionados ao angioedema adquirido com deficiência do inibidor de C1 ou angioedema hereditário que são menos comuns, mas muito importantes pela possibilidade de desfecho fatal. O angioedema hereditário é uma doença rara, caracterizada por crises de edema que acometem o tecido subcutâneo e mucosas de vários órgãos, manifestando-se principalmente por crises de angioedema e dor abdominal. Esse tipo de angioedema não responde ao tratamento usual com adrenalina, anti-histamínicos e corticosteroides. Assim, se não identificados e tratados adequadamente, esses pacientes têm risco de morte por edema de laringe estimado em 25% a 40%. O tratamento do angioedema hereditário mudou drasticamente nos últimos anos, com o desenvolvimento de novos e eficientes fármacos para as crises: inibidor de C1 derivado de plasma, inibidor de C1 recombinante humano, antagonista do receptor B2 da bradicinina (icatibanto) e o inibidor da calicreína (ecalantide). No Brasil, até o momento, estão liberados para uso o inibidor de C1 derivado de plasma e o icatibanto. O manejo correto desses pacientes na emergência evita cirurgias desnecessárias e, principalmente, desfechos fatais.
Sujets)
Humains , Angio-oedèmes héréditaires/diagnostic , Angio-oedèmes héréditaires/traitement médicamenteux , Angioedème/diagnostic , Angioedème/traitement médicamenteux , Brésil , Inhibiteurs de l'enzyme de conversion de l'angiotensine/usage thérapeutique , Service hospitalier d'urgencesRésumé
Abstract This second joint document, written by experts from the Brazilian Association of Allergy and Immunology (ASBAI) and Brazilian Society of Anesthesiology (SBA) concerned with perioperative anaphylaxis, aims to review the pathophysiological reaction mechanisms, triggering agents (in adults and children), and the approach for diagnosis during and after an episode of anaphylaxis. As anaphylaxis assessment is extensive, the identification of medications, antiseptics and other substances used at each setting, the comprehensive data documentation, and the use of standardized nomenclature are key points for obtaining more consistent epidemiological information on perioperative anaphylaxis.
Resumo Este segundo documento, escrito por especialistas da Associação Brasileira de Alergia e Imunologia (ASBAI) e da Sociedade Brasileira de Anestesiologia (SBA) interessados no tema anafilaxia perioperatória, tem por objetivo revisar os mecanismos fisiopatológicos, agentes desencadeantes (em adultos e crianças), assim como a abordagem diagnóstica durante e após o episódio. Por se tratar de uma avaliação abrangente, a identificação das medicações, antissépticos e outras substâncias usadas em cada região, registros detalhados, e nomenclatura padronizada são pontos fundamentais para a obtenção de dados epidemiológicos mais fidedignos sobre a anafilaxia perioperatória.
Sujets)
Humains , Enfant , Adulte , Hypersensibilité médicamenteuse/diagnostic , Hypersensibilité médicamenteuse/étiologie , Période périopératoire , Anaphylaxie/diagnostic , Anaphylaxie/étiologie , Sociétés médicales , Vasodilatateurs/effets indésirables , Techniques in vitro , Mastocytose/complications , Brésil , Soins préopératoires , Immunoglobuline E/immunologie , Bradykinine/effets indésirables , Tests cutanés/méthodes , Facteurs de risque , Déficit en IgA/complications , Hypersensibilité médicamenteuse/physiopathologie , Allergie et immunologie , Évaluation des symptômes , Anaphylaxie/physiopathologie , Anesthésiologie , Angioedème/induit chimiquement , Terminologie comme sujetRésumé
Abstract Experts from the Brazilian Association of Allergy and Immunology (ASBAI) and the Brazilian Society of Anesthesiology (SBA) interested in the issue of perioperative anaphylaxis, and aiming to strengthen the collaboration between the two societies, combined efforts to study the topic and to prepare a joint document to guide specialists in both areas. The purpose of the present series of two articles was to report the most recent evidence based on the collaborative assessment between both societies. This first article will consider the updated definitions, treatment and guidelines after a perioperative crisis. The following article will discuss the major etiologic agents, how to proceed with the investigation, and the appropriate tests.
Resumo Especialistas da Associação Brasileira de Alergia e Imunologia (ASBAI) e da Sociedade Brasileira de Anestesiologia (SBA) interessados no tema anafilaxia perioperatória reuniram-se com o objetivo de intensificar a colaboração entre as duas sociedades no estudo desse tema e elaborar um documento conjunto que possa guiar os especialistas de ambas as áreas. O objetivo desta série de dois artigos foi mostrar as evidências mais recentes alicerçadas na visão colaborativa entre as sociedades. Este primeiro artigo versará sobre as definições mais atuais, formas de tratamento e as orientações após a crise no perioperatório. No próximo artigo serão discutidos os principais agentes causais e a condução da investigação com testes apropriados.
Sujets)
Humains , Enfant , Adulte , Hypersensibilité médicamenteuse/diagnostic , Hypersensibilité médicamenteuse/étiologie , Période périopératoire , Anaphylaxie/diagnostic , Anaphylaxie/étiologie , Sociétés médicales , Vasodilatateurs/effets indésirables , Techniques in vitro , Mastocytose/complications , Brésil , Soins préopératoires , Immunoglobuline E/immunologie , Bradykinine/effets indésirables , Tests cutanés/méthodes , Facteurs de risque , Déficit en IgA/complications , Hypersensibilité médicamenteuse/physiopathologie , Allergie et immunologie , Évaluation des symptômes , Anaphylaxie/physiopathologie , Anesthésiologie , Angioedème/induit chimiquement , Terminologie comme sujetRésumé
ABSTRACT: COVID-19 is a new disease, whose several atypical clinical manifestations began to be observed with the evolution of the pandemic, and have been investigated to understand the pathophysiology of the disease. In this article, the objective is to describe a case of angioedema in COVID-19, considered an atypical manifestation, and rarely described in the literature. The case is of a 55-year-old patient who sought medical attention for a complaint of intermittent fever for four days. On the seventh day, he manifested angioedema in the left zygomatic projection and the right subpalpebral region. The patient had no history of angioedema earlier in life. The following day, he presented a regression of the angioedema concerning the previous day. After this period, the patient progressed well and became asymptomatic. The RT-PCR laboratory test performed on the first days of manifesting symptoms was positive for SARS-CoV-2. We correlate the onset of angioedema with the possible endotheliitis present in the disease, which has been evidenced by the observation of severe endothelial injury associated with the intracellular presence of the virus in several histopathological studies of patients with COVID-19. Also, possible deregulation of the Kininogen-Kallikrein-Kinin System (KKKS) could explain this manifestation, as SARS-CoV-2 binds to the ACE2 receptor, which is responsible for degrading kinins, such as bradykinin. (AU)
RESUMO: A COVID-19 é uma doença nova, cujas diversas manifestações clínicas atípicas começaram a ser observadas com a evolução da pandemia e foram investigadas com o objetivo de compreender a fisiopatologia da doença. Neste artigo, o objetivo é descrever um caso de angioedema no COVID-19, considerado manifestação atípica e raramente descrito na literatura. O caso é de um paciente de 55 anos que procurou atendimento médico por uma queixa de febre intermitente há quatro dias. No sétimo dia, manifestou angioedema na projeção zigomática esquerda e na região subpalpebral direita. Não tinha histórico de apresentar angioedema. No dia seguinte, ele apresentou regressão do angioedema em relação ao dia anterior. Após esse período, o paciente progrediu bem e tornou-se assintomático. O teste laboratorial de RT-PCR realizado nos primeiros dias de manifestação dos sintomas foi positivo para SARS-CoV-2. Correlacionamos o início do angioedema com a possível endotelite presente na doença, o que foi evidenciado pela observação de lesão endotelial grave associada à presença intracelular do vírus em vários estudos histopatológicos de pacientes com COVID-19. Além disso, uma possível desregulação do sistema Cininogênio-Calicreína-Cinina poderia explicar essa manifestação, já que o SARS-CoV-2 se liga ao receptor ACE2, responsável pela degradação de cininas, como a bradicinina. (AU)
Sujets)
Humains , Mâle , Adulte d'âge moyen , Bradykinine , Infections à coronavirus , Endothélium , Pandémies , SARS-CoV-2 , AngioedèmeRésumé
A urticária é uma doença comum, determinada pela ativação de mastócitos que se apresenta por urticas, angioedema, ou ambos. Convencionou-se classificar a urticária, quanto a sua duração, em duas formas: aguda (UA) e crônica (UC). A urticária é definida como crônica quando persiste por 6 semanas ou mais. A urticária crônica compreende urticária crônica espontânea (UCE) e urticárias crônicas induzidas (UCInd), que incluem as urticárias físicas e não físicas. Estudos sugerem que a presença de UCInd associada a UCE está ligada a um pior prognóstico e duração da doença. Essa revisão tem por objetivo atualizar as informações disponíveis sobre a prevalência, quadros clínicos, métodos diagnósticos e tratamentos das UCInd por estímulos físicos ou não.
Urticaria is a common disease determined by the activation of mast cells that presents with urticaria, angioedema, or both. According to its duration, urticaria is classified into two forms: acute (AU) and chronic (CU). Urticaria is defined as CU when it persists for 6 weeks or more. CU consists of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), which includes physical and nonphysical urticarias. Studies suggest that the presence of both CIndU and CSU is linked to worse prognosis and longer duration of these diseases. This review aims to update available information on the prevalence, clinical manifestations, diagnostic methods, and treatments of CIndU by physical or nonphysical stimuli.
Sujets)
Humains , Urticaire chronique , Pronostic , Thérapeutique , Urticaire , Tests cutanés , Prévalence , Angioedème , Mastocytes , MéthodesRésumé
Introdução: A urticária colinérgica (UCol) é um subtipo de urticária crônica induzida, desencadeada pela sudorese e o aumento da temperatura corporal. A associação de UCol com atopia é referida como um possível subtipo mais grave. A manifestação de angioedema estaria associada a um quadro mais prolongado de urticária e a sintomas extracutâneos, por exemplo, anafilaxia. Objetivo: Avaliar a frequência de atopia e/ou angioedema nos pacientes com UCol, em um centro terciário. Métodos: Estudo retrospectivo de prontuários de pacientes com UCol acompanhados em um centro terciário. Todos apresentavam teste de provocação para UCol positivo. A frequência de atopia e/ou angioedema foi avaliada nestes pacientes, como também as características gerais nestes subgrupos. Resultados: Foram incluídos 30 pacientes, sendo 60% do gênero feminino e idade (média) de 32,9 anos e tempo de doença (média) de 7,5 anos. O angioedema foi referido por 8 pacientes (26,7%), não foram observadas diferenças significantes entre os dois grupos (com e sem angioedema). Em relação à atopia, 9 pacientes (30%) realizaram a investigação através de IgE específica para aeroalérgenos, sendo positivo em 6 destes (66,7%). Embora sem diferença estatística, o grupo de pacientes com UCol e atopia apresentava valores de IgE sérica total mais elevados e maior frequência de associação com outras urticárias induzidas. Conclusões: Neste estudo, a frequência de atopia foi elevada e associada a níveis elevados de IgE sérica total. O angioedema foi relatado em mais de um quarto dos pacientes, independente da associação com UCE, favorecendo a uma maior gravidade à UCol. Doze pacientes (40%) não responderam aos anti-histamínicos, apesar da dose quadruplicada, sendo necessários outros esquemas terapêuticos.
Introduction: Cholinergic urticaria (CholU) is a subtype of chronic induced urticaria that is triggered by sweating and increased body temperature. The association of CholU with atopy is referred to as a possible subtype but more severe. The manifestation of angioedema is believed to be associated with more prolonged urticaria and extracutaneous symptoms such as anaphylaxis. Objective: To assess the frequency of atopy and/or angioedema in patients with CholU in a tertiary care center. Methods: A retrospective study of medical records of patients with CholU followed-up at a tertiary care center was conducted. All patients had a positive test for CholU. The frequency of atopy and/or angioedema was assessed in these patients, as well as the general characteristics in the subgroups. Results: Thirty patients were included in the study; 60% were female, mean age was 32.9 years, and mean disease duration was 7.5 years. Angioedema was reported by eight patients (26.7%). There were no significant differences between the two groups (with and without angioedema). Concerning atopy, nine patients (30%) underwent investigation using specific IgE for aeroallergens, with six positive results (66.7%). Although there was no statistical difference, the group of patients with CholU and atopy had higher total serum IgE values and a higher frequency of association with other induced urticaria. Conclusions: In this study, the frequency of atopy was high and associated with high levels of total serum IgE. Angioedema was reported in more than a quarter of patients, regardless of the association with ECU , favoring greater severity of ChoIU. Twelve patients (40%) did not respond to antihistamines, despite the quadrupled dose, requiring other therapeutic regimens.
Sujets)
Humains , Urticaire chronique , Angioedème , Patients , Signes et symptômes , Sudation , Thérapeutique , Température du corps , Immunoglobuline E , Dossiers médicaux , Études rétrospectives , Agents cholinergiques , Antihistaminiques , AnaphylaxieRésumé
Angioedema vibratório é uma forma rara de urticária induzida, que pode ser de caráter familiar ou adquirido. Este artigo descreve um caso clínico de uma mulher, com 33 anos de idade, fisioterapeuta, que iniciou sinais de edema e dor local após atividades de lazer ainda na adolescência e se intensificou posteriormente durante atividades profissionais. Aspectos fisiopatológicos foram discutidos, assim como avaliação laboratorial e testes de provocação. Objetivamos com este relato, ressaltar uma patologia incomum, mas que pode ter grande impacto na qualidade de vida do paciente, necessitando assim de um olhar minucioso do médico na prática clínica. Entendemos que neste caso o angioedema vibratório é efetivamente uma doença ocupacional. Constatamos que de modo geral para urticárias crônicas induzidas e no particular para angioedema vibratório, a história clínica minuciosa é a melhor forma de se obter o diagnóstico.
Vibratory angioedema is a rare form of induced urticaria, which can have a family or acquired etiology. This article describes a clinical case of a 33-year-old, female physiotherapist presenting with signs of edema and local pain after leisure activities that started in her adolescence and intensified during professional activities. Pathophysiological aspects were discussed, as well as laboratory evaluation and provocation tests. With this report, we aim to discuss an unusual disease that can have a major impact on patient's quality of life, thus requiring a detailed look at the physician's clinical practice. We understand that, in the reported case, vibratory angioedema is effectively an occupational disease. We found that in general for chronic induced urticaria and in particular for vibratory angioedema, a thorough clinical history is the best way to obtain the diagnosis.